Identification of the Secretogranin II-Derived Peptide EM66 in Pheochromocytomas as a Potential Marker for Discriminating BenignVersusMalignant Tumors-Reference-Cited by-同舟云学术

Identification of the Secretogranin II-Derived Peptide EM66 in Pheochromocytomas as a Potential Marker for Discriminating BenignVersusMalignant Tumors

Published:2003-06 Issue:6 Volume:88 Page:2579-2585
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:The Journal of Clinical Endocrinology & Metabolism

Author:

Yon Laurent,Guillemot Johann,Montero-Hadjadje Maite,Grumolato Luca,Leprince Jerome,Lefebvre Herve,Contesse Vincent,Plouin Pierre-François,Vaudry Hubert,Anouar Youssef

Publisher

The Endocrine Society

Subject

Biochemistry, medical,Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential Expression of Secretogranins II and III in Canine Adrenal Chromaffin Cells and Pheochromocytomas;Journal of Histochemistry & Cytochemistry;2022-04-09

2. Identification of an immune gene-associated prognostic signature in patients with bladder cancer;Cancer Gene Therapy;2022-02-15

3. Identification of a prognostic gene signature based on an immunogenomic landscape analysis of bladder cancer;Journal of Cellular and Molecular Medicine;2020-10-13

4. Intricacies of the Molecular Machinery of Catecholamine Biosynthesis and Secretion by Chromaffin Cells of the Normal Adrenal Medulla and in Pheochromocytoma and Paraganglioma;Cancers;2019-08-06

5. Characterization of the EM66 Biomarker in the Pituitary and Plasma of Healthy Subjects With Different Gonadotroph Status and Patients With Gonadotroph Tumor;Frontiers in Endocrinology;2019-02-22